Swiss drug major Roche says that its developmental rheumatoid arthritis treatment Actemra (tocilizumab) has met its primary efficacy endpoint, defined as a significant reduction in the disease signs and symptoms, in a Phase III study in patients with moderate-to-severe forms of the illness who had previously failed to respond to anti-tumor necrosis factor-based therapy.
The assessment, known as RADIATE, sought to examine the drug in combination with one of two doses of methotrexate (4mg/kg or 8mg/kg), in comparison with placebo, in the treatment 498 RA sufferers at 13 sites across the world. The results showed that the combined regimen brought about a greater symptom reduction than methotrexate plus placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze